{"gene":"ZNF148","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":1996,"finding":"ZBP-89 (ZNF148) is a Krüppel-type C2H2 zinc finger transcription factor that binds specifically to the GC-rich gastrin EGF response element (GGGGCGGGGTGGGGGG) and inhibits both basal and EGF-induced gastrin promoter activity, functioning as a transcriptional repressor that competes with Sp1 at the same DNA element.","method":"Expression library screening, EMSA, reporter gene assays, in vitro binding assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (library screen, EMSA, reporter assay), founding mechanistic paper replicated in multiple subsequent studies","pmids":["8943318"],"is_preprint":false},{"year":1998,"finding":"ZBP-89 binds to the GC box in the ornithine decarboxylase (ODC) promoter and inhibits Sp1-mediated activation of the ODC promoter. ZBP-89 was identified as the protein responsible for NF-ODC1 binding activity: ZBP-89 co-purified with NF-ODC1 activity, anti-ZBP-89 antibodies abolished NF-ODC1 binding, and the binding affinities of ZBP-89 and NF-ODC1 for 12 oligonucleotides were indistinguishable.","method":"Yeast one-hybrid screening, co-purification, antibody supershift, competitive binding assays, reporter gene assays in Drosophila SL2 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — three independent lines of biochemical evidence in one study, functionally validated by reporter assay","pmids":["9685330"],"is_preprint":false},{"year":1997,"finding":"ZBP-89 overexpression inhibits cell proliferation: DNA synthesis is inhibited and progression to S phase is blocked in immortalized GH4 and malignant AGS cell lines, at least in part through repression of ornithine decarboxylase promoter activity.","method":"3H-thymidine incorporation, BrdU labeling, flow cytometry, reporter gene assay (ODC promoter)","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal readouts in one lab, single study","pmids":["9268691"],"is_preprint":false},{"year":2000,"finding":"ZBP-89 binds to the human vimentin gene silencer element and heterodimerizes with Sp1 at this element. Co-immunoprecipitation and DNA affinity chromatography showed that Sp1 and ZBP-89 form a complex when bound to the silencer element.","method":"In vivo DMS footprinting (ligation-mediated PCR), EMSA, UV cross-linking, Southwestern blot, co-immunoprecipitation, DNA affinity chromatography","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical methods in one study, interaction confirmed by two independent approaches (Co-IP and DNA affinity chromatography)","pmids":["10777586"],"is_preprint":false},{"year":2000,"finding":"ZBP-89 directly binds p300 (histone acetyltransferase co-activator) via its N-terminal domain, but does not directly bind Sp1. ZBP-89 co-precipitates with Sp1, and deletion of the ZBP-89 N-terminal domain abolishes both the p300 interaction and butyrate-mediated potentiation of p21(waf1) transcription. ZBP-89 binds to a specific element at -245 to -215 in the p21(waf1) promoter.","method":"Adenoviral overexpression, co-immunoprecipitation, DNase I footprinting, EMSA, deletion mutagenesis, reporter gene assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with recombinant protein, mutagenesis defining domain requirements, Co-IP showing selective interaction; multiple orthogonal methods in one rigorous study","pmids":["10899165"],"is_preprint":false},{"year":2000,"finding":"PTRF (polymerase I and transcript-release factor) interacts with the N-terminal zinc-finger domain of BFCOL1/ZBP-89 (identified by yeast two-hybrid), and recombinant PTRF enhances BFCOL1 binding to the mouse proalpha2(I) collagen proximal promoter in vitro. PTRF has a suppressive effect on collagen promoter activity in transfection assays.","method":"Yeast two-hybrid, recombinant protein binding assay, transient transfection reporter assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus in vitro functional validation, single lab","pmids":["10727401"],"is_preprint":false},{"year":2001,"finding":"ZBP-89 stabilizes p53 protein and enhances p53 transcriptional activity through direct protein-protein interaction. The DNA binding and C-terminal domains of p53 and the zinc finger domain of ZBP-89 mediate the interaction. ZBP-89 retains p53 in the nucleus (shown by heterokaryon assay) without preventing MDM2-p53 interaction. The p53 R273H mutation greatly reduced ZBP-89-mediated stabilization. Elevated ZBP-89 induces growth arrest and apoptosis in human gastrointestinal cell lines.","method":"Co-immunoprecipitation, domain deletion/point-mutation analysis, heterokaryon nuclear export assay, reporter gene assay, flow cytometry","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — domain mapping by mutagenesis, mechanistic nuclear retention demonstrated by heterokaryon assay, Co-IP, multiple orthogonal methods in one rigorous study","pmids":["11416144"],"is_preprint":false},{"year":2003,"finding":"ZBP-89 represses vimentin gene transcription by interacting with the transcriptional activator Sp1 via its N-terminal domain. The glutamine-rich region of Sp1 is required for vimentin activation, while ZBP-89 N-terminus mediates interaction with Sp1 and represses expression. Overexpression of hTAF(II)130 alleviates ZBP-89 repression.","method":"Transient transfection reporter assay, deletion constructs, overexpression in Schneider (S2) cells","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mapping by deletion constructs plus functional rescue by hTAF(II)130, single lab","pmids":["12771217"],"is_preprint":false},{"year":2003,"finding":"ZBP-89 is required for constitutive STAT1 expression. A G-rich element (+171 to +179) in the first intron of STAT1 is critical for STAT1 promoter activity. ZBP-89 binds this element along with Sp1 and Sp3. siRNA-mediated reduction of ZBP-89 attenuated both basal and IFNγ-induced STAT1 expression and diminished caspase-3 and PARP activation.","method":"Site-directed mutagenesis, EMSA, siRNA knockdown, immunoblotting, reporter assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis identifies critical element, siRNA knockdown with functional readout, single lab","pmids":["14654702"],"is_preprint":false},{"year":2004,"finding":"ZBP-89 induces apoptosis through a p53-independent mechanism requiring JNK activation. ZBP-89 activates JNK via repression of JNK dephosphorylation by downregulating the dual-specificity phosphatase MKP6. ZBP-89-induced apoptosis proceeds through the mitochondrial pathway; JNK inhibition (by peptide inhibitor or dominant-negative JNK2) abrogates apoptosis, while ERK inhibition enhances it. ZBP-89 represses Bcl-xL and Mcl-1 expression.","method":"Ectopic expression, dominant-negative constructs, kinase inhibitors, protein dephosphorylation assays, oligonucleotide microarray, siRNA silencing, PARP cleavage assays","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (pharmacological inhibition, dominant-negative, siRNA, microarray) converge on JNK/MKP6 mechanism; single lab but comprehensive","pmids":["14963412"],"is_preprint":false},{"year":2006,"finding":"ZBP-89 interacts with ATM in a butyrate/HDACi-dependent manner and recruits ATM to GC-rich elements of the p21(waf1) promoter. Co-immunoprecipitation revealed ATM associates with both the N-terminal and DNA binding domains of ZBP-89. Immunodepletion of ZBP-89 prevented recruitment of ATM to the p21(waf1) promoter in vitro. Silencing ZBP-89 blocked HDACi-induced phosphorylation of ATM(Ser1981) and p53(Ser15).","method":"Co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation (ChIP), DNA affinity precipitation, siRNA, serial deletion mapping","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods including immunodepletion of ZBP-89 blocking ATM recruitment in vitro, Co-IP, ChIP, and siRNA, in one comprehensive study","pmids":["16952553"],"is_preprint":false},{"year":2007,"finding":"ATM phosphorylates ZBP-89 at Ser202 (within an SQ motif in the zinc finger domain) both in vitro and in vivo. Disruption of the ATM phosphorylation motif (S202A) attenuated ZBP-89's ability to enhance p21(waf1) activation by butyrate and abrogated potentiation of butyrate-induced endogenous p21(waf1) expression.","method":"In vitro kinase assay, site-directed mutagenesis (S202A), reporter gene assay, immunoblotting","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis of phosphorylation site with functional consequences, single lab","pmids":["17560543"],"is_preprint":false},{"year":2007,"finding":"ZBP-89 is post-translationally modified by SUMO at two conserved synergy control motifs flanking the DNA binding domain. Sumoylation inhibits functional cooperation (synergy) between ZBP-89 and Sp1 at promoters bearing multiple response elements, and inhibits ZBP-89 synergy with heterologous activators such as glucocorticoid receptor, through a conserved functional surface. Sumoylation does not directly alter ZBP-89's ability to compete with Sp-like factors from individual sites.","method":"Sumoylation assay, mutagenesis of SUMO acceptor sites, reporter gene assays, promoter analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — post-translational modification identified with mutagenesis of acceptor sites and multiple functional readouts, single lab","pmids":["17940278"],"is_preprint":false},{"year":2008,"finding":"ZBP-89 is a component of multiprotein complexes involving GATA-1 and its cofactor FOG-1 in erythroid and megakaryocyte cells (identified by proteomics). ZBP-89 and GATA-1 co-occupy cis-regulatory elements of certain erythroid and megakaryocyte-specific genes by chromatin immunoprecipitation. Loss of ZBP-89 function in zebrafish and mice demonstrates an in vivo requirement for ZBP-89 in megakaryopoiesis and definitive erythropoiesis but not primitive erythropoiesis.","method":"Proteomics (GATA-1 interactome), chromatin immunoprecipitation, morpholino knockdown in zebrafish, mouse genetic knockout","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — proteomic identification plus ChIP validation plus genetic loss-of-function in two organisms, convergent evidence","pmids":["18250154"],"is_preprint":false},{"year":2009,"finding":"ZBP-89 suppresses p16(INK4a) expression through an epigenetic mechanism: ZBP-89 recruits HDAC3 (not HDAC4) to the p16(INK4a) promoter, resulting in histone deacetylation. Knockdown of ZBP-89 stimulates cellular senescence reversible by p16 silencing. ZBP-89 and HDAC3 form a complex (shown by co-immunoprecipitation and immunofluorescence co-localization).","method":"siRNA knockdown, chromatin immunoprecipitation, co-immunoprecipitation, immunofluorescence, beta-galactosidase senescence assay, reporter gene assay","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP demonstrating HDAC3 recruitment plus functional senescence phenotype rescued by p16 silencing; multiple orthogonal methods, single lab","pmids":["19583777"],"is_preprint":false},{"year":2009,"finding":"ZBP-89 plays a positive role in C2C12 myogenesis: overexpression promotes down-regulation of Pax7 and up-regulation of MRF4 and MyoD, p21, and Rb, while down-regulating cyclinA and cyclinD1. ZBP-89 levels increase during myogenesis, and siRNA-mediated ZBP-89 knockdown delays the myogenic program. ChIP assays confirmed ZBP-89 occupancy at target gene loci.","method":"Adenoviral overexpression, siRNA knockdown, qRT-PCR, chromatin immunoprecipitation, flow cytometry","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — overexpression and knockdown with multiple readouts plus ChIP, single lab","pmids":["19232372"],"is_preprint":false},{"year":2011,"finding":"ZBP-89 physically associates with histone acetyltransferases p300 and Gcn5/Trrap in erythroid cells, and occupies common chromatin sites with Gcn5 within human globin loci. ZBP-89 knockdown results in reduced Gcn5 occupancy, decreased histone H3 acetylation, and lower globin and erythroid-specific gene expression.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, lentiviral shRNA knockdown, HDAC inhibitor (valproic acid) rescue","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifies interaction, ChIP demonstrates co-occupancy, shRNA knockdown shows functional consequence, HDAC inhibitor rescue confirms epigenetic mechanism; multiple orthogonal methods","pmids":["21828133"],"is_preprint":false},{"year":2013,"finding":"ZBP-89 is required for butyrate-induced expression of tryptophan hydroxylase 1 (Tph1) gene in intestinal epithelial enterochromaffin cells. Direct binding of ZBP-89 to the mouse Tph1 promoter was demonstrated by DNA affinity precipitation. Conditional intestinal deletion of ZBP-89 (using VillinCre) abolished butyrate-induced 5-HT production and increased susceptibility to S. typhimurium infection.","method":"Conditional knockout mouse (VillinCre × Zfp148(FL/FL)), microarray, DNA affinity precipitation, infection model","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with direct DNA binding demonstrated by affinity precipitation, in vivo infectious disease phenotype, microarray; multiple orthogonal methods","pmids":["23395646"],"is_preprint":false},{"year":2013,"finding":"ZBP-89 upregulates Bak expression epigenetically by downregulating HDAC3 expression, suppressing HDAC and DNMT activities, maintaining histone acetylation, inhibiting MeCP2 binding, and demethylating CpG islands in the Bak promoter in hepatocellular carcinoma cells.","method":"Adenoviral overexpression, HDAC activity assay, DNMT activity assay, chromatin immunoprecipitation, bisulfite sequencing, xenograft mouse model","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple epigenetic assays plus in vivo xenograft confirmation, single lab","pmids":["23954442"],"is_preprint":false},{"year":2014,"finding":"Zfp148 deficiency increases p53 activity and reduces atherosclerosis by causing proliferation arrest of lesional macrophages. The anti-atherosclerotic effect of Zfp148 deficiency depends on p53 (epistasis: Zfp148 heterozygosity had no effect on atherosclerosis in Trp53+/- mice). Macrophages from Zfp148(gt/+) mice showed increased phospho-p53. Bone marrow transplantation established the effector cell is hematopoietic.","method":"Gene-trap mouse model, bone marrow transplantation, Trp53 epistasis cross, phospho-p53 immunostaining, BrdU proliferation assay","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with p53 null mice directly demonstrates pathway dependency, bone marrow transplantation identifies cell type, multiple orthogonal methods","pmids":["25212213"],"is_preprint":false},{"year":2014,"finding":"ZBP-89 directly represses PU.1 transcription and activates SCL/Tal1 and GATA-1 transcription in hematopoietic cells. Conditional deletion of ZBP-89 in adult HSPCs causes transient anemia and thrombocytopenia, and a myeloid-to-B lymphoid lineage switch after bone marrow transplantation, associated with upregulation of PU.1 and downregulation of SCL/Tal1 and GATA-1.","method":"Conditional knockout, bone marrow transplantation, chromatin immunoprecipitation, luciferase reporter assay, siRNA in FDCP-Mix A4 cells, flow cytometry","journal":"Stem cells","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP and luciferase reporter identify direct transcriptional targets, conditional KO with bone marrow transplantation establishes in vivo lineage role, multiple orthogonal methods","pmids":["24549639"],"is_preprint":false},{"year":2015,"finding":"ZBP-89 attenuates HDAC3 levels by inducing IκB phosphorylation and degradation (independent of NF-κB transcriptional activity), and this process partially depends on Pin1. ZBP-89 forms a complex with IκB. Pin1 knockout cells show significantly less ZBP-89-mediated HDAC3 and IκB reduction.","method":"Co-immunoprecipitation, inhibitor studies (CAY10576, MG132, SN50), Pin1 knockout cells, siRNA, adenoviral overexpression, xenograft tumor model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus pharmacological dissection of pathway plus genetic (Pin1 KO) validation, single lab","pmids":["25623232"],"is_preprint":false},{"year":2016,"finding":"ZBP-89 drives a feedforward loop of β-catenin expression in colorectal cancer: ZBP-89 binds a site in the proximal CTNNB1 promoter and induces its transcription (identified by ChIP and EMSA). Reciprocally, β-catenin/TCF signaling induces ZNF148 gene expression (TCF sites identified in ZNF148 promoter by ChIP). Conditional deletion of Zfp148 in APC-deleted mice reduces polyp formation.","method":"Chromatin immunoprecipitation, EMSA, siRNA, conditional knockout mouse, reporter gene assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP and EMSA identify direct binding, reciprocal siRNA experiments, conditional KO in mouse model; multiple orthogonal methods","pmids":["27758879"],"is_preprint":false},{"year":2017,"finding":"ZNF148 binds allele-specifically to rs36115365-C in the CLPTM1L/TERT locus at chr5p15.33, confirmed by proteomic pulldown and binding of purified recombinant ZNF148. ZNF148 knockdown reduces TERT expression, telomerase activity, and telomere length.","method":"Proteomic binding assay (allele-specific), recombinant protein binding, siRNA knockdown, telomerase activity assay, telomere length measurement","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — recombinant protein binding plus proteomic identification plus functional knockdown with multiple readouts (TERT, telomerase, telomere length), single study","pmids":["28447668"],"is_preprint":false},{"year":2019,"finding":"ZBP-89 negatively regulates liver cancer stem cell (LCSC) self-renewal via inhibition of Notch1 signaling. ZBP-89 localizes in the nucleus with the Notch1 intracellular domain (NICD1) and represses Notch1 signaling by competitively binding NICD1 with MAML1.","method":"Exogenous expression, sphere formation assay, co-immunoprecipitation, xenograft mouse model, competitive binding assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifies NICD1 interaction, competitive binding with MAML1 demonstrated, in vivo xenograft model; single lab","pmids":["31874246"],"is_preprint":false},{"year":2019,"finding":"Zfp148 and its paralog Zfp281 play functionally redundant roles during erythropoiesis. Zfp281 physically associates with GATA-1, occupies common chromatin sites with GATA-1 and Zfp148, and combined deficiency of Zfp148 and Zfp281 causes a marked erythroid maturation block beyond that seen with either alone.","method":"Conditional knockout mouse (Zfp148 and Zfp281), co-immunoprecipitation, chromatin immunoprecipitation, flow cytometry, shRNA knockdown","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-KO epistasis, Co-IP of protein interaction, ChIP of co-occupancy; multiple orthogonal methods","pmids":["31455666"],"is_preprint":false},{"year":2019,"finding":"Zfp148 (along with Klf4 and Klf2) activates autophagy-related genes in smooth muscle cells during aortic aneurysm formation. Zfp148 siRNA inhibits activation of autophagy genes (Beclin, LC3). ChIP demonstrates Zfp148 binds autophagy gene loci in smooth muscle cells after elastase treatment.","method":"siRNA knockdown, chromatin immunoprecipitation, qPCR, elastase/IL-1β treatment in vitro","journal":"Physiological reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown plus ChIP binding evidence, single lab","pmids":["31025534"],"is_preprint":false},{"year":2020,"finding":"ZNF148 is phosphorylated by ERK at Ser306, and this phosphorylation causes ZNF148 to bind Forkhead box M1 (FOXM1). ZNF148 and FOXM1 form a complex at promoters, where ZNF148 facilitates histone H3 acetylation and FOXM1-mediated Snail transcription, promoting tumor cell invasion in SDHB-deficient GIST.","method":"Phosphorylation assay, co-immunoprecipitation, chromatin immunoprecipitation, reporter gene assay, invasion assay","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation identified, Co-IP and ChIP support complex formation and function, single lab","pmids":["32060966"],"is_preprint":false},{"year":2020,"finding":"Zfp148 deficiency downregulates cell cycle genes in mouse embryonic fibroblasts in a p53-dependent manner, and this proliferation arrest requires increased expression of ARF. ChIP showed Zfp148 binds the ARF promoter, suggesting direct repression of ARF transcription by Zfp148. Zfp148 deficiency preferentially bound to promoters of transcription factors, suggesting indirect effects also activate ARF and p53.","method":"Chromatin immunoprecipitation (ChIP-seq), mouse embryonic fibroblast proliferation assays, p53/ARF genetic epistasis, CRISPR/siRNA screen data analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq identifies direct ARF promoter binding, genetic epistasis with p53/ARF, but note: authors report no genetic interaction between ZNF148 and TP53 in human cancer cells (negative result in human cells)","pmids":["32843651"],"is_preprint":false},{"year":2022,"finding":"ZNF148 is a direct transcriptional target repressed by MYC in breast cancer. ZNF148 transcriptionally represses Inhibitor of DNA binding 1 (ID1) and ID3, drivers of cancer stemness. ZNF148 depletion by shRNA and CRISPR/Cas9 increases TNBC cell proliferation and migration. Global transcriptome and chromatin occupancy analyses (ChIP-seq) confirmed ZNF148 occupancy at ID1/ID3 loci.","method":"shRNA knockdown, CRISPR/Cas9 deletion, RNA-seq, ChIP-seq, chromatin occupancy analysis","journal":"Oncogenesis","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO plus shRNA, RNA-seq plus ChIP-seq identifying ID1/ID3 as direct targets; multiple orthogonal methods in one rigorous study","pmids":["36207293"],"is_preprint":false},{"year":2022,"finding":"β cell-specific deletion of Zfp148 (β-Zfp148KO) improves glucose-stimulated Ca2+ oscillations and enhances amino acid-induced Ca2+ influx independent of glycolysis (suggesting enhanced PEP cycling). ZNF148 deletion alters expression of enzymes involved in amino acid and intermediary metabolism (SLC3A2, SLC7A8, GLS, GLS2, PSPH, PHGDH, PSAT1, GOT1, PCK2) and enhances insulin secretion in response to L-glutamine.","method":"Conditional knockout mouse (β cell-specific Zfp148 deletion), Ca2+ imaging, RNA-seq, proteomics","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with Ca2+ imaging plus RNA-seq plus proteomics; multiple orthogonal methods identifying metabolic mechanism, single lab","pmids":["35603790"],"is_preprint":false},{"year":2023,"finding":"ZNF148 reduction in human islets and deletion in SC-β cells enhances insulin secretion. ZNF148 represses S100A16 expression, which prevents translocation of annexin A2 from nucleus to cell membrane. ZNF148 deletion de-represses annexin-S100 complexes involved in insulin vesicle trafficking and exocytosis.","method":"siRNA knockdown in human islets, CRISPR/Cas9 deletion in SC-β cells, transcriptomics, insulin secretion assay, subcellular fractionation","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — human islet knockdown plus SC-β cell CRISPR KO, transcriptomics identifying direct target (S100A16), subcellular localization change; multiple orthogonal methods in rigorous study","pmids":["37288664"],"is_preprint":false},{"year":2023,"finding":"ZNF148 is a transcriptional activator of the wild-type TERT promoter: ZNF148 binds specifically to the WT TERT promoter at position 124 and upregulates TERT transcription and telomerase activity. ZNF148 shows reduced interaction with the -124C>T mutant allele. Identified by proteomics screen for allele-specific binders.","method":"Proteomics (allele-specific pulldown), reporter gene assay, telomerase activity assay","journal":"Genome research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic identification with functional reporter and telomerase activity validation, single lab","pmids":["37918959"],"is_preprint":false},{"year":2023,"finding":"Zfp148 and Zfp281 control CD4+ T cell thymic development: they promote intrathymic CD4+ T cell differentiation including expression of the CD4+ lineage-committing factor Thpok. In peripheral TH2 cells, Zfp148 promotes chromatin opening at and expression of TH2 cytokine genes but not of Gata3. Zfp281 physically interacts with Gata3 and is recruited to Gata3 genomic binding sites at Thpok and TH2 cytokine loci.","method":"Genetic conditional knockout, single-cell RNA-seq, spatial transcriptomics, co-immunoprecipitation (Zfp281-Gata3), ATAC-seq","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with single-cell transcriptomics plus ATAC-seq plus Co-IP; comprehensive multi-method study (note: Zfp281-Gata3 interaction is for the paralog but Zfp148 genetic contribution established)","pmids":["37948511"],"is_preprint":false},{"year":2024,"finding":"ZNF148 inhibits HBV replication by binding to the RXRα promoter and downregulating RXRα transcription. Overexpression of ZNF148 decreases HBV RNAs, HBV core DNA, and cccDNA transcriptional activity. RXRα overexpression or mutation of its ZNF148 binding site abolishes ZNF148's suppressive effect on HBV replication.","method":"Dual-luciferase reporter assay, Northern blot, Southern blot, Western blot, overexpression/siRNA knockdown, rcccDNA mouse model","journal":"Virology journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay identifies direct promoter binding, rescue experiments with RXRα confirm pathway, in vivo mouse model; single lab","pmids":["38297280"],"is_preprint":false},{"year":2025,"finding":"ZNF148 physically binds p63 in head and neck squamous cell carcinoma cells (identified by proteomics, validated by co-immunoprecipitation). p63 and ZNF148 co-occupy a functional transcribed enhancer-derived RNA (eRNA) upstream of the CCND1 gene, controlling its transcription and overexpression of cyclin D1 to promote tumor cell proliferation. This axis is specific to cancer cells and inactive in normal epithelial cells.","method":"Proteomics (p63 pulldown), co-immunoprecipitation, chromatin occupancy (ChIP-seq), eRNA reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomics plus Co-IP for protein interaction, ChIP-seq for co-occupancy, eRNA functional assay; multiple orthogonal methods, recent peer-reviewed study","pmids":["40623191"],"is_preprint":false},{"year":2026,"finding":"ZFP148 is a transcriptional repressor of cytolytic CD8+ T cell effector differentiation. ZFP148 deficiency increases cytolytic effector CD8+ T cells and reduces exhausted T cells during chronic viral infection. Mechanistically, ZFP148 limits chromatin accessibility at effector-driving transcription factor motifs and directly represses expression of KLF2. Conditional ZFP148 ablation synergizes with PD-1 blockade in tumor models.","method":"Conditional knockout (Zfp148fl/fl), chronic viral infection model, ATAC-seq, ChIP-seq or CUT&RUN, flow cytometry, syngeneic tumor models, immunotherapy combination","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with ATAC-seq identifying chromatin mechanism, direct target (KLF2) identified, in vivo tumor and viral infection models; multiple orthogonal methods in rigorous study","pmids":["41896465"],"is_preprint":false}],"current_model":"ZNF148 (ZBP-89) is a Krüppel-type C2H2 zinc finger transcription factor that binds GC-rich DNA elements to activate or repress target genes (including p21(waf1), gastrin, vimentin, STAT1, Tph1, CTNNB1, TERT, KLF2, ID1/3, S100A16, and others), forms functional complexes with p300, GATA-1, FOG-1, Sp1, ATM, HDAC3, p63, NICD1, and Gcn5/Trrap, is post-translationally modified by SUMO (inhibiting synergistic activation) and phosphorylated by ATM at Ser202 (potentiating p21 induction), stabilizes and retains p53 in the nucleus via direct protein interaction to promote growth arrest and apoptosis, and plays defined roles in hematopoiesis, erythropoiesis, myogenesis, intestinal epithelial homeostasis, β-cell insulin secretion, CD4+ and CD8+ T cell differentiation, and tumor suppression."},"narrative":{"mechanistic_narrative":"ZNF148 (ZBP-89/BFCOL1) is a Krüppel-type C2H2 zinc finger transcription factor that binds GC-rich DNA elements to repress or activate target genes and thereby governs cell proliferation, differentiation, and tissue homeostasis [PMID:8943318, PMID:10899165]. At its founding it was defined as a repressor of the gastrin promoter that competes with Sp1 at a shared GC-rich element [PMID:8943318], and it similarly represses the ODC and vimentin promoters by competing with or directly heterodimerizing with Sp1 [PMID:9685330, PMID:10777586, PMID:12771217]. Its transcriptional output is determined by the co-regulators it recruits: it binds the histone acetyltransferases p300 and Gcn5/Trrap [PMID:10899165, PMID:21828133] and the deacetylase HDAC3 [PMID:19583777], using these to acetylate erythroid and globin loci [PMID:21828133] or to epigenetically silence p16(INK4a) [PMID:19583777]. ZNF148 is a central node in p53/ARF-dependent growth control, directly stabilizing and nuclear-retaining p53 through a zinc-finger/p53-DNA-binding-domain interaction [PMID:11416144] and repressing the ARF promoter [PMID:32843651]; its loss arrests proliferation in a p53-dependent manner in macrophages and fibroblasts [PMID:25212213, PMID:32843651]. It also induces p21(waf1) by recruiting ATM to the promoter, and ATM reciprocally phosphorylates ZNF148 at Ser202 to potentiate this induction [PMID:16952553, PMID:17560543]. Activity is further tuned by SUMOylation, which restrains synergy with Sp1 and other activators [PMID:17940278]. Through these mechanisms ZNF148 directs hematopoietic lineage choice and erythropoiesis as part of GATA-1/FOG-1 complexes and in redundancy with its paralog Zfp281 [PMID:18250154, PMID:24549639, PMID:31455666], drives a β-catenin feedforward loop in colorectal tumorigenesis [PMID:27758879], regulates TERT transcription and telomerase activity [PMID:28447668, PMID:37918959], and restrains insulin secretion, T-cell differentiation, and CD8+ effector/exhaustion programs [PMID:35603790, PMID:37288664, PMID:37948511, PMID:41896465]. Across these contexts it functions context-dependently as both tumor suppressor and tumor promoter [PMID:36207293, PMID:40623191].","teleology":[{"year":1996,"claim":"Established ZNF148/ZBP-89 as a sequence-specific GC-rich DNA-binding repressor, defining the protein's core molecular activity by showing it competes with Sp1 at the gastrin promoter.","evidence":"Expression library screen, EMSA, and reporter assays at the gastrin EGF response element","pmids":["8943318"],"confidence":"High","gaps":["Co-regulators mediating repression not yet identified","In vivo relevance untested"]},{"year":1998,"claim":"Generalized the Sp1-antagonism model to a second GC-box target, showing ZBP-89 inhibits Sp1-mediated ODC promoter activation, linking DNA binding to growth-related gene control.","evidence":"Yeast one-hybrid, co-purification, antibody supershift, and reporter assays in Drosophila SL2 cells","pmids":["9685330"],"confidence":"High","gaps":["Whether repression is competitive or co-regulator-dependent unresolved at this stage"]},{"year":1997,"claim":"Connected ZBP-89 transcriptional activity to a cellular phenotype by showing overexpression blocks S-phase entry, at least partly via ODC repression.","evidence":"Thymidine/BrdU incorporation, flow cytometry, and ODC reporter assays in GH4/AGS cells","pmids":["9268691"],"confidence":"Medium","gaps":["Single lab, single study","Mechanism linking ODC repression to arrest not fully dissected"]},{"year":2000,"claim":"Resolved how ZBP-89 controls target output by showing it directly binds p300 via its N-terminus and physically partners Sp1, providing the co-activator/co-repressor logic behind p21(waf1) and vimentin regulation.","evidence":"Co-IP, DNase I footprinting, deletion mutagenesis, and reporter assays (p21 and vimentin promoters)","pmids":["10899165","10777586","12771217"],"confidence":"High","gaps":["Whether p300 and HDAC recruitment are mutually exclusive unclear","Context determinants of activation vs repression not defined"]},{"year":2001,"claim":"Defined a co-factor mechanism for tumor suppression by demonstrating ZBP-89 directly binds, stabilizes, and nuclear-retains p53, enhancing p53 activity and driving growth arrest/apoptosis.","evidence":"Co-IP, domain mapping, heterokaryon nuclear export assay, and flow cytometry in GI cell lines","pmids":["11416144"],"confidence":"High","gaps":["Mechanism of p53 stabilization independent of MDM2 not fully resolved","In vivo significance addressed only later"]},{"year":2004,"claim":"Showed ZBP-89 can also trigger apoptosis independently of p53 via JNK activation and MKP6/Bcl-xL/Mcl-1 repression, establishing a parallel death pathway.","evidence":"Dominant-negative JNK, kinase inhibitors, siRNA, and microarray with PARP cleavage readouts","pmids":["14963412"],"confidence":"High","gaps":["Direct vs indirect repression of MKP6 not distinguished","Single lab"]},{"year":2007,"claim":"Established a reciprocal ATM–ZBP-89 signaling module: ZBP-89 recruits ATM to the p21 promoter and ATM phosphorylates ZBP-89 at Ser202 to potentiate p21 induction.","evidence":"Co-IP, ChIP, immunodepletion, in vitro kinase assay, and S202A mutagenesis","pmids":["16952553","17560543"],"confidence":"High","gaps":["Structural basis of ATM recruitment unknown","Generality beyond HDACi context untested"]},{"year":2007,"claim":"Identified SUMOylation at synergy-control motifs as a post-translational switch restraining ZBP-89 cooperation with Sp1 and other activators without altering simple site competition.","evidence":"SUMOylation assays, acceptor-site mutagenesis, and reporter assays","pmids":["17940278"],"confidence":"High","gaps":["SUMO ligase/protease controlling this not identified","Physiological triggers of SUMOylation unknown"]},{"year":2009,"claim":"Demonstrated an epigenetic silencing mechanism whereby ZBP-89 recruits HDAC3 to deacetylate the p16(INK4a) promoter, with loss driving senescence reversible by p16 silencing.","evidence":"siRNA, ChIP, Co-IP, immunofluorescence, and beta-galactosidase senescence assays","pmids":["19583777"],"confidence":"High","gaps":["Selectivity for HDAC3 over other HDACs mechanism unclear","Single lab"]},{"year":2008,"claim":"Placed ZBP-89 in hematopoietic transcriptional complexes by showing it associates with GATA-1/FOG-1, co-occupies erythroid/megakaryocyte loci, and is genetically required for definitive erythropoiesis and megakaryopoiesis in vivo.","evidence":"GATA-1 interactome proteomics, ChIP, zebrafish morpholino, and mouse knockout","pmids":["18250154"],"confidence":"High","gaps":["Direct vs bridged GATA-1 interaction not defined","Target genes mediating phenotype incompletely mapped"]},{"year":2011,"claim":"Linked ZBP-89 to acetyltransferase recruitment in erythroid cells by showing it binds p300 and Gcn5/Trrap and is required for Gcn5 occupancy and globin gene H3 acetylation.","evidence":"Co-IP, ChIP co-occupancy, shRNA, and HDAC-inhibitor rescue in erythroid cells","pmids":["21828133"],"confidence":"High","gaps":["How ZBP-89 toggles between HAT and HDAC partners not resolved"]},{"year":2014,"claim":"Defined ZBP-89 as a hematopoietic lineage regulator that represses PU.1 while activating SCL/Tal1 and GATA-1, with deletion causing a myeloid-to-B lymphoid switch.","evidence":"Conditional knockout, bone marrow transplantation, ChIP, and luciferase reporters","pmids":["24549639"],"confidence":"High","gaps":["Direct vs indirect contributions to each target not fully separated"]},{"year":2014,"claim":"Provided in vivo genetic proof that ZBP-89 restrains the p53 pathway by showing Zfp148 deficiency reduces atherosclerosis in a strictly p53-dependent, macrophage-intrinsic manner.","evidence":"Gene-trap mouse, bone marrow transplantation, Trp53 epistasis, and phospho-p53/BrdU readouts","pmids":["25212213"],"confidence":"High","gaps":["Molecular link from ZBP-89 loss to p53 activation defined only later via ARF"]},{"year":2020,"claim":"Mechanistically connected ZBP-89 to p53 activation by identifying direct ARF promoter binding/repression, with loss driving ARF- and p53-dependent cell-cycle arrest.","evidence":"ChIP-seq, MEF proliferation assays, and p53/ARF genetic epistasis","pmids":["32843651"],"confidence":"Medium","gaps":["No genetic ZNF148–TP53 interaction observed in human cancer cells (negative result)","Indirect contributions to ARF activation not fully resolved"]},{"year":2016,"claim":"Identified a β-catenin feedforward loop in colorectal cancer in which ZBP-89 activates CTNNB1 and is itself induced by β-catenin/TCF, with deletion reducing polyps.","evidence":"ChIP, EMSA, siRNA, reporter assays, and conditional KO in APC-deleted mice","pmids":["27758879"],"confidence":"High","gaps":["Co-regulators converting ZBP-89 into a CTNNB1 activator unknown"]},{"year":2017,"claim":"Established allele-specific regulation of telomerase by showing ZNF148 binds the rs36115365-C CLPTM1L/TERT locus and is required for TERT expression, telomerase activity, and telomere length.","evidence":"Allele-specific proteomic pulldown, recombinant protein binding, siRNA, and telomerase/telomere assays","pmids":["28447668"],"confidence":"High","gaps":["Whether effect is activating or repressive at this locus clarified by later TERT promoter work"]},{"year":2023,"claim":"Showed ZNF148 directly activates the wild-type TERT promoter at position -124 and binds the mutant allele poorly, defining it as an activating telomerase regulator.","evidence":"Allele-specific proteomic pulldown, reporter assays, and telomerase activity assays","pmids":["37918959"],"confidence":"Medium","gaps":["Co-activators at the TERT promoter not identified","Single lab"]},{"year":2019,"claim":"Expanded ZNF148's regulatory repertoire across tissues, demonstrating paralog redundancy with Zfp281 in erythropoiesis, NICD1-competitive repression of Notch in liver cancer stem cells, and activation of autophagy genes in smooth muscle.","evidence":"Double conditional KO with Co-IP/ChIP; competitive binding and xenografts; siRNA/ChIP in smooth muscle","pmids":["31455666","31874246","31025534"],"confidence":"High","gaps":["Degree of functional overlap with Zfp281 across other tissues unmapped"]},{"year":2022,"claim":"Defined opposing oncogenic and tumor-suppressive roles by showing ZNF148 is MYC-repressed and itself represses stemness drivers ID1/ID3 in breast cancer.","evidence":"shRNA, CRISPR/Cas9, RNA-seq, and ChIP-seq identifying direct ID1/ID3 targets","pmids":["36207293"],"confidence":"High","gaps":["Determinants of tumor-suppressor vs promoter behavior across cancers unclear"]},{"year":2022,"claim":"Revealed a metabolic role in β cells, where Zfp148 deletion enhances amino-acid-induced Ca2+ influx and insulin secretion by remodeling amino acid/intermediary metabolism gene expression.","evidence":"β-cell-specific conditional KO with Ca2+ imaging, RNA-seq, and proteomics","pmids":["35603790"],"confidence":"High","gaps":["Direct vs indirect transcriptional control of metabolic enzymes not fully dissected"]},{"year":2023,"claim":"Identified an exocytosis-regulatory mechanism whereby ZNF148 represses S100A16 to control annexin A2 trafficking and insulin vesicle exocytosis.","evidence":"siRNA in human islets, CRISPR KO in SC-β cells, transcriptomics, and subcellular fractionation","pmids":["37288664"],"confidence":"High","gaps":["Whether S100A16 repression is direct not fully established"]},{"year":2023,"claim":"Established T-lineage roles by showing Zfp148 (with Zfp281) drives intrathymic CD4+ differentiation and TH2 cytokine chromatin opening.","evidence":"Conditional KO, single-cell RNA-seq, spatial transcriptomics, ATAC-seq, and Co-IP","pmids":["37948511"],"confidence":"High","gaps":["Zfp148's own protein partners in T cells less defined than the paralog's Gata3 interaction"]},{"year":2020,"claim":"Showed ZNF148 phosphorylation by ERK at Ser306 reprograms it into a FOXM1 partner that promotes Snail transcription and invasion in SDHB-deficient GIST.","evidence":"Phosphorylation assays, Co-IP, ChIP, reporter, and invasion assays","pmids":["32060966"],"confidence":"Medium","gaps":["Single lab","Generality of ERK-driven ZNF148/FOXM1 axis beyond GIST untested"]},{"year":2025,"claim":"Demonstrated a cancer-specific enhancer mechanism in which ZNF148 physically binds p63 and co-occupies a CCND1 eRNA to drive cyclin D1 and proliferation.","evidence":"Proteomics, Co-IP, ChIP-seq, and eRNA reporter assays in HNSCC","pmids":["40623191"],"confidence":"High","gaps":["Why the axis is silent in normal epithelium not mechanistically resolved"]},{"year":2026,"claim":"Defined ZFP148 as a brake on cytolytic CD8+ T-cell effector differentiation by limiting effector-TF chromatin accessibility and directly repressing KLF2, with ablation synergizing with PD-1 blockade.","evidence":"Conditional KO, chronic infection and tumor models, ATAC-seq, ChIP-seq/CUT&RUN, and immunotherapy combination","pmids":["41896465"],"confidence":"High","gaps":["Upstream signals controlling ZFP148 in T cells unknown","Full effector-program target set beyond KLF2 incomplete"]},{"year":null,"claim":"It remains unresolved what molecular switch dictates whether ZNF148 acts as activator or repressor and tumor suppressor or promoter at a given locus, including how post-translational modifications and partner availability select between HAT and HDAC recruitment.","evidence":"No single study in the timeline reconciles the activating, repressing, suppressive, and oncogenic functions into one predictive model","pmids":[],"confidence":"Low","gaps":["No unifying structural or biochemical model of activation vs repression","Genome-wide rules linking modification state to co-regulator choice undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,20,22,29,36]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,3,17,23,28]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,10,24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,24]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[4,10,16,35]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,4,20,29]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,4,14,28]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,9,18]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[14,16,18,36]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[33,36]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[22,29,35]}],"complexes":["GATA-1/FOG-1 complex","ZBP-89–HDAC3 complex","ZBP-89–p300/Gcn5–Trrap complex"],"partners":["SP1","EP300","TP53","ATM","HDAC3","GATA1","FOXM1","TP63"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UQR1","full_name":"Zinc finger protein 148","aliases":["Transcription factor ZBP-89","Zinc finger DNA-binding protein 89"],"length_aa":794,"mass_kda":89.0,"function":"Involved in transcriptional regulation. Represses the transcription of a number of genes including gastrin, stromelysin and enolase. Binds to the G-rich box in the enhancer region of these genes","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9UQR1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF148","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"KPNA1","stoichiometry":0.2},{"gene":"PHAX","stoichiometry":0.2},{"gene":"RABIF","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZNF148","total_profiled":1310},"omim":[{"mim_id":"618703","title":"ZINC FINGER PROTEIN 281; ZNF281","url":"https://www.omim.org/entry/618703"},{"mim_id":"617260","title":"GLOBAL DEVELOPMENTAL DELAY, ABSENT OR HYPOPLASTIC CORPUS CALLOSUM, AND DYSMORPHIC FACIES; GDACCF","url":"https://www.omim.org/entry/617260"},{"mim_id":"601897","title":"ZINC FINGER PROTEIN 148; ZNF148","url":"https://www.omim.org/entry/601897"},{"mim_id":"601796","title":"TAF4 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 135-KD; TAF4","url":"https://www.omim.org/entry/601796"},{"mim_id":"193060","title":"VIMENTIN; VIM","url":"https://www.omim.org/entry/193060"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZNF148"},"hgnc":{"alias_symbol":["BERF-1","ZBP-89","BFCOL1","HT-BETA","ZFP148","pHZ-52"],"prev_symbol":[]},"alphafold":{"accession":"Q9UQR1","domains":[{"cath_id":"3.30.160.60","chopping":"169-222","consensus_level":"medium","plddt":86.5252,"start":169,"end":222}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UQR1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UQR1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UQR1-F1-predicted_aligned_error_v6.png","plddt_mean":46.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF148","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF148"},"sequence":{"accession":"Q9UQR1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UQR1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UQR1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UQR1"}},"corpus_meta":[{"pmid":"8943318","id":"PMC_8943318","title":"ZBP-89, a Krüppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8943318","citation_count":119,"is_preprint":false},{"pmid":"10899165","id":"PMC_10899165","title":"Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10899165","citation_count":100,"is_preprint":false},{"pmid":"11416144","id":"PMC_11416144","title":"ZBP-89 promotes growth arrest through stabilization of p53.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11416144","citation_count":96,"is_preprint":false},{"pmid":"12524542","id":"PMC_12524542","title":"Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12524542","citation_count":78,"is_preprint":false},{"pmid":"9685330","id":"PMC_9685330","title":"Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9685330","citation_count":76,"is_preprint":false},{"pmid":"18250154","id":"PMC_18250154","title":"Identification of ZBP-89 as a novel GATA-1-associated transcription factor involved in megakaryocytic and erythroid development.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18250154","citation_count":63,"is_preprint":false},{"pmid":"12771217","id":"PMC_12771217","title":"ZBP-89 represses vimentin gene transcription by interacting with the transcriptional activator, Sp1.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12771217","citation_count":58,"is_preprint":false},{"pmid":"19583777","id":"PMC_19583777","title":"The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence.","date":"2009","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19583777","citation_count":56,"is_preprint":false},{"pmid":"10777586","id":"PMC_10777586","title":"The zinc finger repressor, ZBP-89, binds to the silencer element of the human vimentin gene and complexes with the transcriptional activator, Sp1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10777586","citation_count":56,"is_preprint":false},{"pmid":"10359087","id":"PMC_10359087","title":"Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10359087","citation_count":53,"is_preprint":false},{"pmid":"28447668","id":"PMC_28447668","title":"Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28447668","citation_count":52,"is_preprint":false},{"pmid":"10727401","id":"PMC_10727401","title":"PTRF (polymerase I and transcript-release factor) is tissue-specific and interacts with the BFCOL1 (binding factor of a type-I collagen promoter) zinc-finger transcription factor which binds to the two mouse type-I collagen gene promoters.","date":"2000","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/10727401","citation_count":49,"is_preprint":false},{"pmid":"14963412","id":"PMC_14963412","title":"ZBP-89-induced apoptosis is p53-independent and requires JNK.","date":"2004","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/14963412","citation_count":47,"is_preprint":false},{"pmid":"23395646","id":"PMC_23395646","title":"ZBP-89 regulates expression of tryptophan hydroxylase I and mucosal defense against Salmonella typhimurium in mice.","date":"2013","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23395646","citation_count":44,"is_preprint":false},{"pmid":"12759240","id":"PMC_12759240","title":"Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12759240","citation_count":44,"is_preprint":false},{"pmid":"9144414","id":"PMC_9144414","title":"Overexpression of ZBP-89, a zinc finger DNA binding protein, in gastric cancer.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9144414","citation_count":41,"is_preprint":false},{"pmid":"20230874","id":"PMC_20230874","title":"Transcription factor ZBP-89 in cancer growth and apoptosis.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20230874","citation_count":36,"is_preprint":false},{"pmid":"25212213","id":"PMC_25212213","title":"Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53.","date":"2014","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/25212213","citation_count":35,"is_preprint":false},{"pmid":"10757983","id":"PMC_10757983","title":"Three zinc finger nuclear proteins, Sp1, Sp3, and a ZBP-89 homologue, bind to the cyclic adenosine monophosphate-responsive sequence of the bovine adrenodoxin gene and regulate transcription.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10757983","citation_count":35,"is_preprint":false},{"pmid":"31874246","id":"PMC_31874246","title":"ZBP-89 negatively regulates self-renewal of liver cancer stem cells via suppression of Notch1 signaling pathway.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31874246","citation_count":30,"is_preprint":false},{"pmid":"31025534","id":"PMC_31025534","title":"Klf4, Klf2, and Zfp148 activate autophagy-related genes in smooth muscle cells during aortic aneurysm formation.","date":"2019","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/31025534","citation_count":30,"is_preprint":false},{"pmid":"14654702","id":"PMC_14654702","title":"Transcription factor ZBP-89 is required for STAT1 constitutive expression.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/14654702","citation_count":30,"is_preprint":false},{"pmid":"12393719","id":"PMC_12393719","title":"The zinc finger transcription factor ZBP-89 is a repressor of the human beta 2-integrin CD11b gene.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393719","citation_count":30,"is_preprint":false},{"pmid":"9268691","id":"PMC_9268691","title":"ZBP-89, a Krüppel-type zinc finger protein, inhibits cell proliferation.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9268691","citation_count":29,"is_preprint":false},{"pmid":"21828133","id":"PMC_21828133","title":"Role of ZBP-89 in human globin gene regulation and erythroid differentiation.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21828133","citation_count":28,"is_preprint":false},{"pmid":"16914492","id":"PMC_16914492","title":"The transcription factor ZBP-89 controls generation of the hematopoietic lineage in zebrafish and mouse embryonic stem cells.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16914492","citation_count":27,"is_preprint":false},{"pmid":"17940278","id":"PMC_17940278","title":"Sumoylation-dependent control of homotypic and heterotypic synergy by the Kruppel-type zinc finger protein ZBP-89.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17940278","citation_count":25,"is_preprint":false},{"pmid":"17019648","id":"PMC_17019648","title":"Intestinal overexpression of ZNF148 suppresses ApcMin/+ neoplasia.","date":"2006","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/17019648","citation_count":24,"is_preprint":false},{"pmid":"27964749","id":"PMC_27964749","title":"Truncating de novo mutations in the Krüppel-type zinc-finger gene ZNF148 in patients with corpus callosum defects, developmental delay, short stature, and dysmorphisms.","date":"2016","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27964749","citation_count":24,"is_preprint":false},{"pmid":"19275880","id":"PMC_19275880","title":"NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19275880","citation_count":24,"is_preprint":false},{"pmid":"16952553","id":"PMC_16952553","title":"Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.","date":"2006","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16952553","citation_count":24,"is_preprint":false},{"pmid":"27758879","id":"PMC_27758879","title":"Transcription Factor ZBP-89 Drives a Feedforward Loop of β-Catenin Expression in Colorectal Cancer.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27758879","citation_count":23,"is_preprint":false},{"pmid":"12622418","id":"PMC_12622418","title":"Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer.","date":"2002","source":"International journal of gastrointestinal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12622418","citation_count":21,"is_preprint":false},{"pmid":"16517939","id":"PMC_16517939","title":"An isoform of ZBP-89 predisposes the colon to colitis.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16517939","citation_count":21,"is_preprint":false},{"pmid":"15635072","id":"PMC_15635072","title":"A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15635072","citation_count":21,"is_preprint":false},{"pmid":"20850481","id":"PMC_20850481","title":"ZBP-89 enhances Bak expression and causes apoptosis in hepatocellular carcinoma cells.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20850481","citation_count":20,"is_preprint":false},{"pmid":"17560543","id":"PMC_17560543","title":"ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17560543","citation_count":20,"is_preprint":false},{"pmid":"21784970","id":"PMC_21784970","title":"Thyroid transcription factor-1 (TTF-1) gene: identification of ZBP-89, Sp1, and TTF-1 sites in the promoter and regulation by TNF-α in lung epithelial cells.","date":"2011","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21784970","citation_count":20,"is_preprint":false},{"pmid":"28072746","id":"PMC_28072746","title":"ZNF148 modulates TOP2A expression and cell proliferation via ceRNA regulatory mechanism in colorectal cancer.","date":"2017","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28072746","citation_count":19,"is_preprint":false},{"pmid":"19362768","id":"PMC_19362768","title":"ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest.","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19362768","citation_count":19,"is_preprint":false},{"pmid":"19232372","id":"PMC_19232372","title":"Over-expression of the transcription factor, ZBP-89, leads to enhancement of the C2C12 myogenic program.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19232372","citation_count":18,"is_preprint":false},{"pmid":"23954442","id":"PMC_23954442","title":"Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23954442","citation_count":18,"is_preprint":false},{"pmid":"11149424","id":"PMC_11149424","title":"Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11149424","citation_count":18,"is_preprint":false},{"pmid":"22111549","id":"PMC_22111549","title":"Promoter cloning and characterization of the human programmed cell death protein 4 (pdcd4) gene: evidence for ZBP-89 and Sp-binding motifs as essential Pdcd4 regulators.","date":"2012","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/22111549","citation_count":17,"is_preprint":false},{"pmid":"28247213","id":"PMC_28247213","title":"MicroRNA-20b suppresses the expression of ZFP-148 in viral myocarditis.","date":"2017","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28247213","citation_count":17,"is_preprint":false},{"pmid":"36207293","id":"PMC_36207293","title":"A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer.","date":"2022","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36207293","citation_count":16,"is_preprint":false},{"pmid":"37063077","id":"PMC_37063077","title":"Upregulation of the ZNF148/PTX3 axis promotes malignant transformation of dendritic cells in glioma stem-like cells microenvironment.","date":"2023","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37063077","citation_count":16,"is_preprint":false},{"pmid":"23405202","id":"PMC_23405202","title":"Zfp148 deficiency causes lung maturation defects and lethality in newborn mice that are rescued by deletion of p53 or antioxidant treatment.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23405202","citation_count":16,"is_preprint":false},{"pmid":"22214764","id":"PMC_22214764","title":"Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22214764","citation_count":15,"is_preprint":false},{"pmid":"29212231","id":"PMC_29212231","title":"ZBP-89 function in colonic stem cells and during butyrate-induced senescence.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29212231","citation_count":14,"is_preprint":false},{"pmid":"11322790","id":"PMC_11322790","title":"Conserved structure and promoter sequence similarity in the mouse and human genes encoding the zinc finger factor BERF-1/BFCOL1/ZBP-89.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11322790","citation_count":14,"is_preprint":false},{"pmid":"30463804","id":"PMC_30463804","title":"Regulation between two alternative splicing isoforms ZNF148FL and ZNF148ΔN, and their roles in the apoptosis and invasion of colorectal cancer.","date":"2018","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/30463804","citation_count":13,"is_preprint":false},{"pmid":"19505630","id":"PMC_19505630","title":"The transcriptional repressor ZBP-89 and the lack of Sp1/Sp3, c-Jun and Stat3 are important for the down-regulation of the vimentin gene during C2C12 myogenesis.","date":"2009","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/19505630","citation_count":13,"is_preprint":false},{"pmid":"29653560","id":"PMC_29653560","title":"ZBP-89 and Sp1 contribute to Bak expression in hepatocellular carcinoma cells.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29653560","citation_count":12,"is_preprint":false},{"pmid":"33864383","id":"PMC_33864383","title":"Loss of microRNA-147 function alleviates synovial inflammation through ZNF148 in rheumatoid and experimental arthritis.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33864383","citation_count":12,"is_preprint":false},{"pmid":"26891870","id":"PMC_26891870","title":"Zinc-binding protein-89 (ZBP-89) cooperates with NF-κB to regulate expression of matrix metalloproteinases (MMPs) in response to inflammatory cytokines.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26891870","citation_count":12,"is_preprint":false},{"pmid":"27487143","id":"PMC_27487143","title":"Targeting Zfp148 activates p53 and reduces tumor initiation in the gut.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27487143","citation_count":11,"is_preprint":false},{"pmid":"36172162","id":"PMC_36172162","title":"A positive feedback loop between tryptophan hydroxylase 1 and β-Catenin/ZBP-89 signaling promotes prostate cancer progression.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36172162","citation_count":11,"is_preprint":false},{"pmid":"16621236","id":"PMC_16621236","title":"Identification of zinc finger binding protein 89 (ZBP-89) as a transcriptional activator for a major bovine growth hormone receptor promoter.","date":"2006","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16621236","citation_count":11,"is_preprint":false},{"pmid":"37948511","id":"PMC_37948511","title":"Zfp281 and Zfp148 control CD4+ T cell thymic development and TH2 functions.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37948511","citation_count":9,"is_preprint":false},{"pmid":"36710662","id":"PMC_36710662","title":"Identification of the MALAT1/miR-106a-5p/ZNF148 feedback loop in regulating HaCaT cell proliferation, migration and apoptosis.","date":"2023","source":"Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36710662","citation_count":9,"is_preprint":false},{"pmid":"32843651","id":"PMC_32843651","title":"Genomic profiling of the transcription factor Zfp148 and its impact on the p53 pathway.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32843651","citation_count":9,"is_preprint":false},{"pmid":"31455666","id":"PMC_31455666","title":"Zfp281 (ZBP-99) plays a functionally redundant role with Zfp148 (ZBP-89) during erythroid development.","date":"2019","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/31455666","citation_count":9,"is_preprint":false},{"pmid":"24549639","id":"PMC_24549639","title":"Stress hematopoiesis is regulated by the Krüppel-like transcription factor ZBP-89.","date":"2014","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/24549639","citation_count":9,"is_preprint":false},{"pmid":"18496767","id":"PMC_18496767","title":"ZBP-89 and Sp3 down-regulate while NF-Y up-regulates SOX18 promoter activity in HeLa cells.","date":"2008","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/18496767","citation_count":9,"is_preprint":false},{"pmid":"35603790","id":"PMC_35603790","title":"β Cell-specific deletion of Zfp148 improves nutrient-stimulated β cell Ca2+ responses.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35603790","citation_count":8,"is_preprint":false},{"pmid":"9925940","id":"PMC_9925940","title":"The gene encoding the transcriptional repressor BERF-1 maps to a region of conserved synteny on mouse chromosome 16 and human chromosome 3 and a related pseudogene maps to mouse chromosome 8.","date":"1998","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9925940","citation_count":8,"is_preprint":false},{"pmid":"28811660","id":"PMC_28811660","title":"Transcription factor ZNF148 is a negative regulator of human muscle differentiation.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28811660","citation_count":8,"is_preprint":false},{"pmid":"30142986","id":"PMC_30142986","title":"Targeting ZBP-89 for the treatment of hepatocellular carcinoma.","date":"2018","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/30142986","citation_count":7,"is_preprint":false},{"pmid":"32060966","id":"PMC_32060966","title":"Upregulation of ZNF148 in SDHB-deficient gastrointestinal stromal tumor potentiates Forkhead box M1-mediated transcription and promotes tumor cell invasion.","date":"2020","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/32060966","citation_count":7,"is_preprint":false},{"pmid":"20686646","id":"PMC_20686646","title":"Expression of transcription factor zinc-binding protein-89 (ZBP-89) is inhibited by inflammatory cytokines.","date":"2009","source":"Pathology and laboratory medicine international","url":"https://pubmed.ncbi.nlm.nih.gov/20686646","citation_count":6,"is_preprint":false},{"pmid":"16827139","id":"PMC_16827139","title":"P53 mutants suppress ZBP-89 function.","date":"2006","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16827139","citation_count":6,"is_preprint":false},{"pmid":"38297280","id":"PMC_38297280","title":"ZNF148 inhibits HBV replication by downregulating RXRα transcription.","date":"2024","source":"Virology journal","url":"https://pubmed.ncbi.nlm.nih.gov/38297280","citation_count":6,"is_preprint":false},{"pmid":"40623191","id":"PMC_40623191","title":"p63 and ZNF148 cooperate to regulate head and neck squamous cell carcinoma.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40623191","citation_count":5,"is_preprint":false},{"pmid":"36444493","id":"PMC_36444493","title":"Novel de novo ZNF148 truncating variant causing autism spectrum disorder, attention deficit hyperactivity disorder, and intellectual disability.","date":"2022","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36444493","citation_count":5,"is_preprint":false},{"pmid":"37918959","id":"PMC_37918959","title":"E4F1 and ZNF148 are transcriptional activators of the -57A > C and wild-type TERT promoter.","date":"2023","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/37918959","citation_count":3,"is_preprint":false},{"pmid":"37288664","id":"PMC_37288664","title":"Loss of ZNF148 enhances insulin secretion in human pancreatic β cells.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/37288664","citation_count":3,"is_preprint":false},{"pmid":"25623232","id":"PMC_25623232","title":"ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1.","date":"2015","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25623232","citation_count":3,"is_preprint":false},{"pmid":"37580113","id":"PMC_37580113","title":"Further delineation of the rare GDACCF (global developmental delay, absent or hypoplastic corpus callosum, dysmorphic facies syndrome): genotype and phenotype of 22 patients with ZNF148 mutations.","date":"2024","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37580113","citation_count":3,"is_preprint":false},{"pmid":"29242385","id":"PMC_29242385","title":"Differential Regulation of Zfp30 Expression in Murine Airway Epithelia Through Altered Binding of ZFP148 to rs51434084.","date":"2018","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/29242385","citation_count":3,"is_preprint":false},{"pmid":"41020579","id":"PMC_41020579","title":"Hsa_circRNA_0101125 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Carcinoma via miR-143-3p/ZNF148 Axis.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41020579","citation_count":2,"is_preprint":false},{"pmid":"41457142","id":"PMC_41457142","title":"The ZNF148-ZEB1-AS1-IGF2BP2-NOD2 Axis Drives Microglial Antipneumococcal Immunity in Bacterial Meningitis.","date":"2026","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/41457142","citation_count":2,"is_preprint":false},{"pmid":"41896465","id":"PMC_41896465","title":"ZFP148 is a transcriptional repressor of cytolytic effector CD8+ T cell differentiation.","date":"2026","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41896465","citation_count":0,"is_preprint":false},{"pmid":"37572175","id":"PMC_37572175","title":"A Combination of BRAF and EZH1/SPOP/ZNF148 Three-Gene Mutational Classifier Improves Benign Call Rate in Indeterminate Thyroid Nodules.","date":"2023","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37572175","citation_count":0,"is_preprint":false},{"pmid":"38567931","id":"PMC_38567931","title":"A novel 3q interstitial deletion including GATA2 and ZNF148: A case report.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/38567931","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42357,"output_tokens":9998,"usd":0.13852,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":40686,"output_tokens":11711,"usd":0.38547,"resynth_parse_fail":true,"stage2_stop_reason":"end_turn"},"total_usd":0.52399,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"ZBP-89 (ZNF148) is a Krüppel-type C2H2 zinc finger transcription factor that binds specifically to the GC-rich gastrin EGF response element (GGGGCGGGGTGGGGGG) and inhibits both basal and EGF-induced gastrin promoter activity, functioning as a transcriptional repressor that competes with Sp1 at the same DNA element.\",\n      \"method\": \"Expression library screening, EMSA, reporter gene assays, in vitro binding assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (library screen, EMSA, reporter assay), founding mechanistic paper replicated in multiple subsequent studies\",\n      \"pmids\": [\"8943318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ZBP-89 binds to the GC box in the ornithine decarboxylase (ODC) promoter and inhibits Sp1-mediated activation of the ODC promoter. ZBP-89 was identified as the protein responsible for NF-ODC1 binding activity: ZBP-89 co-purified with NF-ODC1 activity, anti-ZBP-89 antibodies abolished NF-ODC1 binding, and the binding affinities of ZBP-89 and NF-ODC1 for 12 oligonucleotides were indistinguishable.\",\n      \"method\": \"Yeast one-hybrid screening, co-purification, antibody supershift, competitive binding assays, reporter gene assays in Drosophila SL2 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — three independent lines of biochemical evidence in one study, functionally validated by reporter assay\",\n      \"pmids\": [\"9685330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ZBP-89 overexpression inhibits cell proliferation: DNA synthesis is inhibited and progression to S phase is blocked in immortalized GH4 and malignant AGS cell lines, at least in part through repression of ornithine decarboxylase promoter activity.\",\n      \"method\": \"3H-thymidine incorporation, BrdU labeling, flow cytometry, reporter gene assay (ODC promoter)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal readouts in one lab, single study\",\n      \"pmids\": [\"9268691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ZBP-89 binds to the human vimentin gene silencer element and heterodimerizes with Sp1 at this element. Co-immunoprecipitation and DNA affinity chromatography showed that Sp1 and ZBP-89 form a complex when bound to the silencer element.\",\n      \"method\": \"In vivo DMS footprinting (ligation-mediated PCR), EMSA, UV cross-linking, Southwestern blot, co-immunoprecipitation, DNA affinity chromatography\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical methods in one study, interaction confirmed by two independent approaches (Co-IP and DNA affinity chromatography)\",\n      \"pmids\": [\"10777586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ZBP-89 directly binds p300 (histone acetyltransferase co-activator) via its N-terminal domain, but does not directly bind Sp1. ZBP-89 co-precipitates with Sp1, and deletion of the ZBP-89 N-terminal domain abolishes both the p300 interaction and butyrate-mediated potentiation of p21(waf1) transcription. ZBP-89 binds to a specific element at -245 to -215 in the p21(waf1) promoter.\",\n      \"method\": \"Adenoviral overexpression, co-immunoprecipitation, DNase I footprinting, EMSA, deletion mutagenesis, reporter gene assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with recombinant protein, mutagenesis defining domain requirements, Co-IP showing selective interaction; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"10899165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PTRF (polymerase I and transcript-release factor) interacts with the N-terminal zinc-finger domain of BFCOL1/ZBP-89 (identified by yeast two-hybrid), and recombinant PTRF enhances BFCOL1 binding to the mouse proalpha2(I) collagen proximal promoter in vitro. PTRF has a suppressive effect on collagen promoter activity in transfection assays.\",\n      \"method\": \"Yeast two-hybrid, recombinant protein binding assay, transient transfection reporter assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus in vitro functional validation, single lab\",\n      \"pmids\": [\"10727401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ZBP-89 stabilizes p53 protein and enhances p53 transcriptional activity through direct protein-protein interaction. The DNA binding and C-terminal domains of p53 and the zinc finger domain of ZBP-89 mediate the interaction. ZBP-89 retains p53 in the nucleus (shown by heterokaryon assay) without preventing MDM2-p53 interaction. The p53 R273H mutation greatly reduced ZBP-89-mediated stabilization. Elevated ZBP-89 induces growth arrest and apoptosis in human gastrointestinal cell lines.\",\n      \"method\": \"Co-immunoprecipitation, domain deletion/point-mutation analysis, heterokaryon nuclear export assay, reporter gene assay, flow cytometry\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — domain mapping by mutagenesis, mechanistic nuclear retention demonstrated by heterokaryon assay, Co-IP, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"11416144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ZBP-89 represses vimentin gene transcription by interacting with the transcriptional activator Sp1 via its N-terminal domain. The glutamine-rich region of Sp1 is required for vimentin activation, while ZBP-89 N-terminus mediates interaction with Sp1 and represses expression. Overexpression of hTAF(II)130 alleviates ZBP-89 repression.\",\n      \"method\": \"Transient transfection reporter assay, deletion constructs, overexpression in Schneider (S2) cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mapping by deletion constructs plus functional rescue by hTAF(II)130, single lab\",\n      \"pmids\": [\"12771217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ZBP-89 is required for constitutive STAT1 expression. A G-rich element (+171 to +179) in the first intron of STAT1 is critical for STAT1 promoter activity. ZBP-89 binds this element along with Sp1 and Sp3. siRNA-mediated reduction of ZBP-89 attenuated both basal and IFNγ-induced STAT1 expression and diminished caspase-3 and PARP activation.\",\n      \"method\": \"Site-directed mutagenesis, EMSA, siRNA knockdown, immunoblotting, reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis identifies critical element, siRNA knockdown with functional readout, single lab\",\n      \"pmids\": [\"14654702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZBP-89 induces apoptosis through a p53-independent mechanism requiring JNK activation. ZBP-89 activates JNK via repression of JNK dephosphorylation by downregulating the dual-specificity phosphatase MKP6. ZBP-89-induced apoptosis proceeds through the mitochondrial pathway; JNK inhibition (by peptide inhibitor or dominant-negative JNK2) abrogates apoptosis, while ERK inhibition enhances it. ZBP-89 represses Bcl-xL and Mcl-1 expression.\",\n      \"method\": \"Ectopic expression, dominant-negative constructs, kinase inhibitors, protein dephosphorylation assays, oligonucleotide microarray, siRNA silencing, PARP cleavage assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (pharmacological inhibition, dominant-negative, siRNA, microarray) converge on JNK/MKP6 mechanism; single lab but comprehensive\",\n      \"pmids\": [\"14963412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ZBP-89 interacts with ATM in a butyrate/HDACi-dependent manner and recruits ATM to GC-rich elements of the p21(waf1) promoter. Co-immunoprecipitation revealed ATM associates with both the N-terminal and DNA binding domains of ZBP-89. Immunodepletion of ZBP-89 prevented recruitment of ATM to the p21(waf1) promoter in vitro. Silencing ZBP-89 blocked HDACi-induced phosphorylation of ATM(Ser1981) and p53(Ser15).\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation (ChIP), DNA affinity precipitation, siRNA, serial deletion mapping\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods including immunodepletion of ZBP-89 blocking ATM recruitment in vitro, Co-IP, ChIP, and siRNA, in one comprehensive study\",\n      \"pmids\": [\"16952553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ATM phosphorylates ZBP-89 at Ser202 (within an SQ motif in the zinc finger domain) both in vitro and in vivo. Disruption of the ATM phosphorylation motif (S202A) attenuated ZBP-89's ability to enhance p21(waf1) activation by butyrate and abrogated potentiation of butyrate-induced endogenous p21(waf1) expression.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis (S202A), reporter gene assay, immunoblotting\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis of phosphorylation site with functional consequences, single lab\",\n      \"pmids\": [\"17560543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZBP-89 is post-translationally modified by SUMO at two conserved synergy control motifs flanking the DNA binding domain. Sumoylation inhibits functional cooperation (synergy) between ZBP-89 and Sp1 at promoters bearing multiple response elements, and inhibits ZBP-89 synergy with heterologous activators such as glucocorticoid receptor, through a conserved functional surface. Sumoylation does not directly alter ZBP-89's ability to compete with Sp-like factors from individual sites.\",\n      \"method\": \"Sumoylation assay, mutagenesis of SUMO acceptor sites, reporter gene assays, promoter analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — post-translational modification identified with mutagenesis of acceptor sites and multiple functional readouts, single lab\",\n      \"pmids\": [\"17940278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZBP-89 is a component of multiprotein complexes involving GATA-1 and its cofactor FOG-1 in erythroid and megakaryocyte cells (identified by proteomics). ZBP-89 and GATA-1 co-occupy cis-regulatory elements of certain erythroid and megakaryocyte-specific genes by chromatin immunoprecipitation. Loss of ZBP-89 function in zebrafish and mice demonstrates an in vivo requirement for ZBP-89 in megakaryopoiesis and definitive erythropoiesis but not primitive erythropoiesis.\",\n      \"method\": \"Proteomics (GATA-1 interactome), chromatin immunoprecipitation, morpholino knockdown in zebrafish, mouse genetic knockout\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — proteomic identification plus ChIP validation plus genetic loss-of-function in two organisms, convergent evidence\",\n      \"pmids\": [\"18250154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZBP-89 suppresses p16(INK4a) expression through an epigenetic mechanism: ZBP-89 recruits HDAC3 (not HDAC4) to the p16(INK4a) promoter, resulting in histone deacetylation. Knockdown of ZBP-89 stimulates cellular senescence reversible by p16 silencing. ZBP-89 and HDAC3 form a complex (shown by co-immunoprecipitation and immunofluorescence co-localization).\",\n      \"method\": \"siRNA knockdown, chromatin immunoprecipitation, co-immunoprecipitation, immunofluorescence, beta-galactosidase senescence assay, reporter gene assay\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP demonstrating HDAC3 recruitment plus functional senescence phenotype rescued by p16 silencing; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"19583777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZBP-89 plays a positive role in C2C12 myogenesis: overexpression promotes down-regulation of Pax7 and up-regulation of MRF4 and MyoD, p21, and Rb, while down-regulating cyclinA and cyclinD1. ZBP-89 levels increase during myogenesis, and siRNA-mediated ZBP-89 knockdown delays the myogenic program. ChIP assays confirmed ZBP-89 occupancy at target gene loci.\",\n      \"method\": \"Adenoviral overexpression, siRNA knockdown, qRT-PCR, chromatin immunoprecipitation, flow cytometry\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — overexpression and knockdown with multiple readouts plus ChIP, single lab\",\n      \"pmids\": [\"19232372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ZBP-89 physically associates with histone acetyltransferases p300 and Gcn5/Trrap in erythroid cells, and occupies common chromatin sites with Gcn5 within human globin loci. ZBP-89 knockdown results in reduced Gcn5 occupancy, decreased histone H3 acetylation, and lower globin and erythroid-specific gene expression.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, lentiviral shRNA knockdown, HDAC inhibitor (valproic acid) rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifies interaction, ChIP demonstrates co-occupancy, shRNA knockdown shows functional consequence, HDAC inhibitor rescue confirms epigenetic mechanism; multiple orthogonal methods\",\n      \"pmids\": [\"21828133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ZBP-89 is required for butyrate-induced expression of tryptophan hydroxylase 1 (Tph1) gene in intestinal epithelial enterochromaffin cells. Direct binding of ZBP-89 to the mouse Tph1 promoter was demonstrated by DNA affinity precipitation. Conditional intestinal deletion of ZBP-89 (using VillinCre) abolished butyrate-induced 5-HT production and increased susceptibility to S. typhimurium infection.\",\n      \"method\": \"Conditional knockout mouse (VillinCre × Zfp148(FL/FL)), microarray, DNA affinity precipitation, infection model\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with direct DNA binding demonstrated by affinity precipitation, in vivo infectious disease phenotype, microarray; multiple orthogonal methods\",\n      \"pmids\": [\"23395646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ZBP-89 upregulates Bak expression epigenetically by downregulating HDAC3 expression, suppressing HDAC and DNMT activities, maintaining histone acetylation, inhibiting MeCP2 binding, and demethylating CpG islands in the Bak promoter in hepatocellular carcinoma cells.\",\n      \"method\": \"Adenoviral overexpression, HDAC activity assay, DNMT activity assay, chromatin immunoprecipitation, bisulfite sequencing, xenograft mouse model\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple epigenetic assays plus in vivo xenograft confirmation, single lab\",\n      \"pmids\": [\"23954442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Zfp148 deficiency increases p53 activity and reduces atherosclerosis by causing proliferation arrest of lesional macrophages. The anti-atherosclerotic effect of Zfp148 deficiency depends on p53 (epistasis: Zfp148 heterozygosity had no effect on atherosclerosis in Trp53+/- mice). Macrophages from Zfp148(gt/+) mice showed increased phospho-p53. Bone marrow transplantation established the effector cell is hematopoietic.\",\n      \"method\": \"Gene-trap mouse model, bone marrow transplantation, Trp53 epistasis cross, phospho-p53 immunostaining, BrdU proliferation assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with p53 null mice directly demonstrates pathway dependency, bone marrow transplantation identifies cell type, multiple orthogonal methods\",\n      \"pmids\": [\"25212213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZBP-89 directly represses PU.1 transcription and activates SCL/Tal1 and GATA-1 transcription in hematopoietic cells. Conditional deletion of ZBP-89 in adult HSPCs causes transient anemia and thrombocytopenia, and a myeloid-to-B lymphoid lineage switch after bone marrow transplantation, associated with upregulation of PU.1 and downregulation of SCL/Tal1 and GATA-1.\",\n      \"method\": \"Conditional knockout, bone marrow transplantation, chromatin immunoprecipitation, luciferase reporter assay, siRNA in FDCP-Mix A4 cells, flow cytometry\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP and luciferase reporter identify direct transcriptional targets, conditional KO with bone marrow transplantation establishes in vivo lineage role, multiple orthogonal methods\",\n      \"pmids\": [\"24549639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZBP-89 attenuates HDAC3 levels by inducing IκB phosphorylation and degradation (independent of NF-κB transcriptional activity), and this process partially depends on Pin1. ZBP-89 forms a complex with IκB. Pin1 knockout cells show significantly less ZBP-89-mediated HDAC3 and IκB reduction.\",\n      \"method\": \"Co-immunoprecipitation, inhibitor studies (CAY10576, MG132, SN50), Pin1 knockout cells, siRNA, adenoviral overexpression, xenograft tumor model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus pharmacological dissection of pathway plus genetic (Pin1 KO) validation, single lab\",\n      \"pmids\": [\"25623232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZBP-89 drives a feedforward loop of β-catenin expression in colorectal cancer: ZBP-89 binds a site in the proximal CTNNB1 promoter and induces its transcription (identified by ChIP and EMSA). Reciprocally, β-catenin/TCF signaling induces ZNF148 gene expression (TCF sites identified in ZNF148 promoter by ChIP). Conditional deletion of Zfp148 in APC-deleted mice reduces polyp formation.\",\n      \"method\": \"Chromatin immunoprecipitation, EMSA, siRNA, conditional knockout mouse, reporter gene assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP and EMSA identify direct binding, reciprocal siRNA experiments, conditional KO in mouse model; multiple orthogonal methods\",\n      \"pmids\": [\"27758879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZNF148 binds allele-specifically to rs36115365-C in the CLPTM1L/TERT locus at chr5p15.33, confirmed by proteomic pulldown and binding of purified recombinant ZNF148. ZNF148 knockdown reduces TERT expression, telomerase activity, and telomere length.\",\n      \"method\": \"Proteomic binding assay (allele-specific), recombinant protein binding, siRNA knockdown, telomerase activity assay, telomere length measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — recombinant protein binding plus proteomic identification plus functional knockdown with multiple readouts (TERT, telomerase, telomere length), single study\",\n      \"pmids\": [\"28447668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZBP-89 negatively regulates liver cancer stem cell (LCSC) self-renewal via inhibition of Notch1 signaling. ZBP-89 localizes in the nucleus with the Notch1 intracellular domain (NICD1) and represses Notch1 signaling by competitively binding NICD1 with MAML1.\",\n      \"method\": \"Exogenous expression, sphere formation assay, co-immunoprecipitation, xenograft mouse model, competitive binding assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifies NICD1 interaction, competitive binding with MAML1 demonstrated, in vivo xenograft model; single lab\",\n      \"pmids\": [\"31874246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Zfp148 and its paralog Zfp281 play functionally redundant roles during erythropoiesis. Zfp281 physically associates with GATA-1, occupies common chromatin sites with GATA-1 and Zfp148, and combined deficiency of Zfp148 and Zfp281 causes a marked erythroid maturation block beyond that seen with either alone.\",\n      \"method\": \"Conditional knockout mouse (Zfp148 and Zfp281), co-immunoprecipitation, chromatin immunoprecipitation, flow cytometry, shRNA knockdown\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-KO epistasis, Co-IP of protein interaction, ChIP of co-occupancy; multiple orthogonal methods\",\n      \"pmids\": [\"31455666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Zfp148 (along with Klf4 and Klf2) activates autophagy-related genes in smooth muscle cells during aortic aneurysm formation. Zfp148 siRNA inhibits activation of autophagy genes (Beclin, LC3). ChIP demonstrates Zfp148 binds autophagy gene loci in smooth muscle cells after elastase treatment.\",\n      \"method\": \"siRNA knockdown, chromatin immunoprecipitation, qPCR, elastase/IL-1β treatment in vitro\",\n      \"journal\": \"Physiological reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown plus ChIP binding evidence, single lab\",\n      \"pmids\": [\"31025534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZNF148 is phosphorylated by ERK at Ser306, and this phosphorylation causes ZNF148 to bind Forkhead box M1 (FOXM1). ZNF148 and FOXM1 form a complex at promoters, where ZNF148 facilitates histone H3 acetylation and FOXM1-mediated Snail transcription, promoting tumor cell invasion in SDHB-deficient GIST.\",\n      \"method\": \"Phosphorylation assay, co-immunoprecipitation, chromatin immunoprecipitation, reporter gene assay, invasion assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation identified, Co-IP and ChIP support complex formation and function, single lab\",\n      \"pmids\": [\"32060966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Zfp148 deficiency downregulates cell cycle genes in mouse embryonic fibroblasts in a p53-dependent manner, and this proliferation arrest requires increased expression of ARF. ChIP showed Zfp148 binds the ARF promoter, suggesting direct repression of ARF transcription by Zfp148. Zfp148 deficiency preferentially bound to promoters of transcription factors, suggesting indirect effects also activate ARF and p53.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP-seq), mouse embryonic fibroblast proliferation assays, p53/ARF genetic epistasis, CRISPR/siRNA screen data analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq identifies direct ARF promoter binding, genetic epistasis with p53/ARF, but note: authors report no genetic interaction between ZNF148 and TP53 in human cancer cells (negative result in human cells)\",\n      \"pmids\": [\"32843651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF148 is a direct transcriptional target repressed by MYC in breast cancer. ZNF148 transcriptionally represses Inhibitor of DNA binding 1 (ID1) and ID3, drivers of cancer stemness. ZNF148 depletion by shRNA and CRISPR/Cas9 increases TNBC cell proliferation and migration. Global transcriptome and chromatin occupancy analyses (ChIP-seq) confirmed ZNF148 occupancy at ID1/ID3 loci.\",\n      \"method\": \"shRNA knockdown, CRISPR/Cas9 deletion, RNA-seq, ChIP-seq, chromatin occupancy analysis\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO plus shRNA, RNA-seq plus ChIP-seq identifying ID1/ID3 as direct targets; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"36207293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"β cell-specific deletion of Zfp148 (β-Zfp148KO) improves glucose-stimulated Ca2+ oscillations and enhances amino acid-induced Ca2+ influx independent of glycolysis (suggesting enhanced PEP cycling). ZNF148 deletion alters expression of enzymes involved in amino acid and intermediary metabolism (SLC3A2, SLC7A8, GLS, GLS2, PSPH, PHGDH, PSAT1, GOT1, PCK2) and enhances insulin secretion in response to L-glutamine.\",\n      \"method\": \"Conditional knockout mouse (β cell-specific Zfp148 deletion), Ca2+ imaging, RNA-seq, proteomics\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with Ca2+ imaging plus RNA-seq plus proteomics; multiple orthogonal methods identifying metabolic mechanism, single lab\",\n      \"pmids\": [\"35603790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF148 reduction in human islets and deletion in SC-β cells enhances insulin secretion. ZNF148 represses S100A16 expression, which prevents translocation of annexin A2 from nucleus to cell membrane. ZNF148 deletion de-represses annexin-S100 complexes involved in insulin vesicle trafficking and exocytosis.\",\n      \"method\": \"siRNA knockdown in human islets, CRISPR/Cas9 deletion in SC-β cells, transcriptomics, insulin secretion assay, subcellular fractionation\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human islet knockdown plus SC-β cell CRISPR KO, transcriptomics identifying direct target (S100A16), subcellular localization change; multiple orthogonal methods in rigorous study\",\n      \"pmids\": [\"37288664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF148 is a transcriptional activator of the wild-type TERT promoter: ZNF148 binds specifically to the WT TERT promoter at position 124 and upregulates TERT transcription and telomerase activity. ZNF148 shows reduced interaction with the -124C>T mutant allele. Identified by proteomics screen for allele-specific binders.\",\n      \"method\": \"Proteomics (allele-specific pulldown), reporter gene assay, telomerase activity assay\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic identification with functional reporter and telomerase activity validation, single lab\",\n      \"pmids\": [\"37918959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Zfp148 and Zfp281 control CD4+ T cell thymic development: they promote intrathymic CD4+ T cell differentiation including expression of the CD4+ lineage-committing factor Thpok. In peripheral TH2 cells, Zfp148 promotes chromatin opening at and expression of TH2 cytokine genes but not of Gata3. Zfp281 physically interacts with Gata3 and is recruited to Gata3 genomic binding sites at Thpok and TH2 cytokine loci.\",\n      \"method\": \"Genetic conditional knockout, single-cell RNA-seq, spatial transcriptomics, co-immunoprecipitation (Zfp281-Gata3), ATAC-seq\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with single-cell transcriptomics plus ATAC-seq plus Co-IP; comprehensive multi-method study (note: Zfp281-Gata3 interaction is for the paralog but Zfp148 genetic contribution established)\",\n      \"pmids\": [\"37948511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZNF148 inhibits HBV replication by binding to the RXRα promoter and downregulating RXRα transcription. Overexpression of ZNF148 decreases HBV RNAs, HBV core DNA, and cccDNA transcriptional activity. RXRα overexpression or mutation of its ZNF148 binding site abolishes ZNF148's suppressive effect on HBV replication.\",\n      \"method\": \"Dual-luciferase reporter assay, Northern blot, Southern blot, Western blot, overexpression/siRNA knockdown, rcccDNA mouse model\",\n      \"journal\": \"Virology journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay identifies direct promoter binding, rescue experiments with RXRα confirm pathway, in vivo mouse model; single lab\",\n      \"pmids\": [\"38297280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF148 physically binds p63 in head and neck squamous cell carcinoma cells (identified by proteomics, validated by co-immunoprecipitation). p63 and ZNF148 co-occupy a functional transcribed enhancer-derived RNA (eRNA) upstream of the CCND1 gene, controlling its transcription and overexpression of cyclin D1 to promote tumor cell proliferation. This axis is specific to cancer cells and inactive in normal epithelial cells.\",\n      \"method\": \"Proteomics (p63 pulldown), co-immunoprecipitation, chromatin occupancy (ChIP-seq), eRNA reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomics plus Co-IP for protein interaction, ChIP-seq for co-occupancy, eRNA functional assay; multiple orthogonal methods, recent peer-reviewed study\",\n      \"pmids\": [\"40623191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ZFP148 is a transcriptional repressor of cytolytic CD8+ T cell effector differentiation. ZFP148 deficiency increases cytolytic effector CD8+ T cells and reduces exhausted T cells during chronic viral infection. Mechanistically, ZFP148 limits chromatin accessibility at effector-driving transcription factor motifs and directly represses expression of KLF2. Conditional ZFP148 ablation synergizes with PD-1 blockade in tumor models.\",\n      \"method\": \"Conditional knockout (Zfp148fl/fl), chronic viral infection model, ATAC-seq, ChIP-seq or CUT&RUN, flow cytometry, syngeneic tumor models, immunotherapy combination\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with ATAC-seq identifying chromatin mechanism, direct target (KLF2) identified, in vivo tumor and viral infection models; multiple orthogonal methods in rigorous study\",\n      \"pmids\": [\"41896465\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF148 (ZBP-89) is a Krüppel-type C2H2 zinc finger transcription factor that binds GC-rich DNA elements to activate or repress target genes (including p21(waf1), gastrin, vimentin, STAT1, Tph1, CTNNB1, TERT, KLF2, ID1/3, S100A16, and others), forms functional complexes with p300, GATA-1, FOG-1, Sp1, ATM, HDAC3, p63, NICD1, and Gcn5/Trrap, is post-translationally modified by SUMO (inhibiting synergistic activation) and phosphorylated by ATM at Ser202 (potentiating p21 induction), stabilizes and retains p53 in the nucleus via direct protein interaction to promote growth arrest and apoptosis, and plays defined roles in hematopoiesis, erythropoiesis, myogenesis, intestinal epithelial homeostasis, β-cell insulin secretion, CD4+ and CD8+ T cell differentiation, and tumor suppression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZNF148 (ZBP-89/BFCOL1) is a Krüppel-type C2H2 zinc finger transcription factor that binds GC-rich DNA elements to repress or activate target genes and thereby governs cell proliferation, differentiation, and tissue homeostasis [#0, #4]. At its founding it was defined as a repressor of the gastrin promoter that competes with Sp1 at a shared GC-rich element [#0], and it similarly represses the ODC and vimentin promoters by competing with or directly heterodimerizing with Sp1 [#1, #3, #7]. Its transcriptional output is determined by the co-regulators it recruits: it binds the histone acetyltransferases p300 and Gcn5/Trrap [#4, #16] and the deacetylase HDAC3 [#14], using these to acetylate erythroid and globin loci [#16] or to epigenetically silence p16(INK4a) [#14]. ZNF148 is a central node in p53/ARF-dependent growth control, directly stabilizing and nuclear-retaining p53 through a zinc-finger/p53-DNA-binding-domain interaction [#6] and repressing the ARF promoter [#28]; its loss arrests proliferation in a p53-dependent manner in macrophages and fibroblasts [#19, #28]. It also induces p21(waf1) by recruiting ATM to the promoter, and ATM reciprocally phosphorylates ZNF148 at Ser202 to potentiate this induction [#10, #11]. Activity is further tuned by SUMOylation, which restrains synergy with Sp1 and other activators [#12]. Through these mechanisms ZNF148 directs hematopoietic lineage choice and erythropoiesis as part of GATA-1/FOG-1 complexes and in redundancy with its paralog Zfp281 [#13, #20, #25], drives a β-catenin feedforward loop in colorectal tumorigenesis [#22], regulates TERT transcription and telomerase activity [#23, #32], and restrains insulin secretion, T-cell differentiation, and CD8+ effector/exhaustion programs [#30, #31, #33, #36]. Across these contexts it functions context-dependently as both tumor suppressor and tumor promoter [#29, #35].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established ZNF148/ZBP-89 as a sequence-specific GC-rich DNA-binding repressor, defining the protein's core molecular activity by showing it competes with Sp1 at the gastrin promoter.\",\n      \"evidence\": \"Expression library screen, EMSA, and reporter assays at the gastrin EGF response element\",\n      \"pmids\": [\"8943318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-regulators mediating repression not yet identified\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Generalized the Sp1-antagonism model to a second GC-box target, showing ZBP-89 inhibits Sp1-mediated ODC promoter activation, linking DNA binding to growth-related gene control.\",\n      \"evidence\": \"Yeast one-hybrid, co-purification, antibody supershift, and reporter assays in Drosophila SL2 cells\",\n      \"pmids\": [\"9685330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether repression is competitive or co-regulator-dependent unresolved at this stage\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Connected ZBP-89 transcriptional activity to a cellular phenotype by showing overexpression blocks S-phase entry, at least partly via ODC repression.\",\n      \"evidence\": \"Thymidine/BrdU incorporation, flow cytometry, and ODC reporter assays in GH4/AGS cells\",\n      \"pmids\": [\"9268691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single study\", \"Mechanism linking ODC repression to arrest not fully dissected\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved how ZBP-89 controls target output by showing it directly binds p300 via its N-terminus and physically partners Sp1, providing the co-activator/co-repressor logic behind p21(waf1) and vimentin regulation.\",\n      \"evidence\": \"Co-IP, DNase I footprinting, deletion mutagenesis, and reporter assays (p21 and vimentin promoters)\",\n      \"pmids\": [\"10899165\", \"10777586\", \"12771217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p300 and HDAC recruitment are mutually exclusive unclear\", \"Context determinants of activation vs repression not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined a co-factor mechanism for tumor suppression by demonstrating ZBP-89 directly binds, stabilizes, and nuclear-retains p53, enhancing p53 activity and driving growth arrest/apoptosis.\",\n      \"evidence\": \"Co-IP, domain mapping, heterokaryon nuclear export assay, and flow cytometry in GI cell lines\",\n      \"pmids\": [\"11416144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of p53 stabilization independent of MDM2 not fully resolved\", \"In vivo significance addressed only later\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed ZBP-89 can also trigger apoptosis independently of p53 via JNK activation and MKP6/Bcl-xL/Mcl-1 repression, establishing a parallel death pathway.\",\n      \"evidence\": \"Dominant-negative JNK, kinase inhibitors, siRNA, and microarray with PARP cleavage readouts\",\n      \"pmids\": [\"14963412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect repression of MKP6 not distinguished\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established a reciprocal ATM–ZBP-89 signaling module: ZBP-89 recruits ATM to the p21 promoter and ATM phosphorylates ZBP-89 at Ser202 to potentiate p21 induction.\",\n      \"evidence\": \"Co-IP, ChIP, immunodepletion, in vitro kinase assay, and S202A mutagenesis\",\n      \"pmids\": [\"16952553\", \"17560543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ATM recruitment unknown\", \"Generality beyond HDACi context untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified SUMOylation at synergy-control motifs as a post-translational switch restraining ZBP-89 cooperation with Sp1 and other activators without altering simple site competition.\",\n      \"evidence\": \"SUMOylation assays, acceptor-site mutagenesis, and reporter assays\",\n      \"pmids\": [\"17940278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO ligase/protease controlling this not identified\", \"Physiological triggers of SUMOylation unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated an epigenetic silencing mechanism whereby ZBP-89 recruits HDAC3 to deacetylate the p16(INK4a) promoter, with loss driving senescence reversible by p16 silencing.\",\n      \"evidence\": \"siRNA, ChIP, Co-IP, immunofluorescence, and beta-galactosidase senescence assays\",\n      \"pmids\": [\"19583777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity for HDAC3 over other HDACs mechanism unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed ZBP-89 in hematopoietic transcriptional complexes by showing it associates with GATA-1/FOG-1, co-occupies erythroid/megakaryocyte loci, and is genetically required for definitive erythropoiesis and megakaryopoiesis in vivo.\",\n      \"evidence\": \"GATA-1 interactome proteomics, ChIP, zebrafish morpholino, and mouse knockout\",\n      \"pmids\": [\"18250154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs bridged GATA-1 interaction not defined\", \"Target genes mediating phenotype incompletely mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Linked ZBP-89 to acetyltransferase recruitment in erythroid cells by showing it binds p300 and Gcn5/Trrap and is required for Gcn5 occupancy and globin gene H3 acetylation.\",\n      \"evidence\": \"Co-IP, ChIP co-occupancy, shRNA, and HDAC-inhibitor rescue in erythroid cells\",\n      \"pmids\": [\"21828133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ZBP-89 toggles between HAT and HDAC partners not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined ZBP-89 as a hematopoietic lineage regulator that represses PU.1 while activating SCL/Tal1 and GATA-1, with deletion causing a myeloid-to-B lymphoid switch.\",\n      \"evidence\": \"Conditional knockout, bone marrow transplantation, ChIP, and luciferase reporters\",\n      \"pmids\": [\"24549639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect contributions to each target not fully separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Provided in vivo genetic proof that ZBP-89 restrains the p53 pathway by showing Zfp148 deficiency reduces atherosclerosis in a strictly p53-dependent, macrophage-intrinsic manner.\",\n      \"evidence\": \"Gene-trap mouse, bone marrow transplantation, Trp53 epistasis, and phospho-p53/BrdU readouts\",\n      \"pmids\": [\"25212213\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link from ZBP-89 loss to p53 activation defined only later via ARF\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mechanistically connected ZBP-89 to p53 activation by identifying direct ARF promoter binding/repression, with loss driving ARF- and p53-dependent cell-cycle arrest.\",\n      \"evidence\": \"ChIP-seq, MEF proliferation assays, and p53/ARF genetic epistasis\",\n      \"pmids\": [\"32843651\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic ZNF148–TP53 interaction observed in human cancer cells (negative result)\", \"Indirect contributions to ARF activation not fully resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified a β-catenin feedforward loop in colorectal cancer in which ZBP-89 activates CTNNB1 and is itself induced by β-catenin/TCF, with deletion reducing polyps.\",\n      \"evidence\": \"ChIP, EMSA, siRNA, reporter assays, and conditional KO in APC-deleted mice\",\n      \"pmids\": [\"27758879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-regulators converting ZBP-89 into a CTNNB1 activator unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established allele-specific regulation of telomerase by showing ZNF148 binds the rs36115365-C CLPTM1L/TERT locus and is required for TERT expression, telomerase activity, and telomere length.\",\n      \"evidence\": \"Allele-specific proteomic pulldown, recombinant protein binding, siRNA, and telomerase/telomere assays\",\n      \"pmids\": [\"28447668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether effect is activating or repressive at this locus clarified by later TERT promoter work\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ZNF148 directly activates the wild-type TERT promoter at position -124 and binds the mutant allele poorly, defining it as an activating telomerase regulator.\",\n      \"evidence\": \"Allele-specific proteomic pulldown, reporter assays, and telomerase activity assays\",\n      \"pmids\": [\"37918959\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-activators at the TERT promoter not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Expanded ZNF148's regulatory repertoire across tissues, demonstrating paralog redundancy with Zfp281 in erythropoiesis, NICD1-competitive repression of Notch in liver cancer stem cells, and activation of autophagy genes in smooth muscle.\",\n      \"evidence\": \"Double conditional KO with Co-IP/ChIP; competitive binding and xenografts; siRNA/ChIP in smooth muscle\",\n      \"pmids\": [\"31455666\", \"31874246\", \"31025534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degree of functional overlap with Zfp281 across other tissues unmapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined opposing oncogenic and tumor-suppressive roles by showing ZNF148 is MYC-repressed and itself represses stemness drivers ID1/ID3 in breast cancer.\",\n      \"evidence\": \"shRNA, CRISPR/Cas9, RNA-seq, and ChIP-seq identifying direct ID1/ID3 targets\",\n      \"pmids\": [\"36207293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of tumor-suppressor vs promoter behavior across cancers unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a metabolic role in β cells, where Zfp148 deletion enhances amino-acid-induced Ca2+ influx and insulin secretion by remodeling amino acid/intermediary metabolism gene expression.\",\n      \"evidence\": \"β-cell-specific conditional KO with Ca2+ imaging, RNA-seq, and proteomics\",\n      \"pmids\": [\"35603790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect transcriptional control of metabolic enzymes not fully dissected\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified an exocytosis-regulatory mechanism whereby ZNF148 represses S100A16 to control annexin A2 trafficking and insulin vesicle exocytosis.\",\n      \"evidence\": \"siRNA in human islets, CRISPR KO in SC-β cells, transcriptomics, and subcellular fractionation\",\n      \"pmids\": [\"37288664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S100A16 repression is direct not fully established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established T-lineage roles by showing Zfp148 (with Zfp281) drives intrathymic CD4+ differentiation and TH2 cytokine chromatin opening.\",\n      \"evidence\": \"Conditional KO, single-cell RNA-seq, spatial transcriptomics, ATAC-seq, and Co-IP\",\n      \"pmids\": [\"37948511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Zfp148's own protein partners in T cells less defined than the paralog's Gata3 interaction\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed ZNF148 phosphorylation by ERK at Ser306 reprograms it into a FOXM1 partner that promotes Snail transcription and invasion in SDHB-deficient GIST.\",\n      \"evidence\": \"Phosphorylation assays, Co-IP, ChIP, reporter, and invasion assays\",\n      \"pmids\": [\"32060966\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Generality of ERK-driven ZNF148/FOXM1 axis beyond GIST untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrated a cancer-specific enhancer mechanism in which ZNF148 physically binds p63 and co-occupies a CCND1 eRNA to drive cyclin D1 and proliferation.\",\n      \"evidence\": \"Proteomics, Co-IP, ChIP-seq, and eRNA reporter assays in HNSCC\",\n      \"pmids\": [\"40623191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why the axis is silent in normal epithelium not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined ZFP148 as a brake on cytolytic CD8+ T-cell effector differentiation by limiting effector-TF chromatin accessibility and directly repressing KLF2, with ablation synergizing with PD-1 blockade.\",\n      \"evidence\": \"Conditional KO, chronic infection and tumor models, ATAC-seq, ChIP-seq/CUT&RUN, and immunotherapy combination\",\n      \"pmids\": [\"41896465\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals controlling ZFP148 in T cells unknown\", \"Full effector-program target set beyond KLF2 incomplete\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved what molecular switch dictates whether ZNF148 acts as activator or repressor and tumor suppressor or promoter at a given locus, including how post-translational modifications and partner availability select between HAT and HDAC recruitment.\",\n      \"evidence\": \"No single study in the timeline reconciles the activating, repressing, suppressive, and oncogenic functions into one predictive model\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying structural or biochemical model of activation vs repression\", \"Genome-wide rules linking modification state to co-regulator choice undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 20, 22, 29, 36]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 3, 17, 23, 28]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 10, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 24]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [4, 10, 16, 35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 4, 20, 29]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 4, 14, 28]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 9, 18]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [14, 16, 18, 36]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [33, 36]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [22, 29, 35]}\n    ],\n    \"complexes\": [\n      \"GATA-1/FOG-1 complex\",\n      \"ZBP-89–HDAC3 complex\",\n      \"ZBP-89–p300/Gcn5–Trrap complex\"\n    ],\n    \"partners\": [\n      \"SP1\",\n      \"EP300\",\n      \"TP53\",\n      \"ATM\",\n      \"HDAC3\",\n      \"GATA1\",\n      \"FOXM1\",\n      \"TP63\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}